Skip links

Publication: Drug Target Review Issue 3 – Features our CEO

Our thanks to Drug Target Review for featuring an article by our CEO and Co-Founder, Randolf Kerschbaumer, highlighting novel capabilities that address elusive therapeutic targets and their impact on the treatment paradigm for patients living with cancer. Download the article here to learn more about our innovative approach and recent developments behind our pipeline of therapeutic antibodies targeting oxMIF.

Home